A study in mice showed that ViaCyte's implant, which contains insulin-producing cells derived from embryonic stem cells, proved to be effective in controlling blood sugar levels for four months. The San Diego-based startup is conducting safety testing that will be used in seeking FDA approval for the human trials of the technology, which is being developed as a treatment for Type 1 diabetes.

Related Summaries